Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan and Capecitabine in Relapsed/Refractory Upper GI Tumours
NCT00220168Phase 4Completed
- Sponsor
- Royal Marsden NHS Foundation Trust
- Start
- Jan 2003
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of irinotecan, capecitabine in esophageal carcinoma, Gastric carcinoma (GC), gastroesophageal junction adenocarcinoma, sponsored by Royal Marsden NHS Foundation Trust. Started Jan 2003; status: completed.
02
Drugs
irinotecancapecitabine
03
Conditions
esophageal carcinomaGastric carcinoma (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT00220168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00220168.